OSAKA -- A Japanese drugmaker plans clinical trials in the U.S. of a regenerative treatment for Parkinson's disease that uses reprogrammed cells, Nikkei has learned.
Osaka-based Sumitomo Dainippon Pharma plans to begin the American trials in fiscal 2022. The goal is to produce a cell transplant treatment that improves the condition of patients with Parkinson's, rather than simply slowing the disease's progress.
